Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Bekaii‐Saab, Tanios , Yaeger, Rona , Spira, Alexander I. , Pelster, Meredith , Sabari, Joshua K. , Hafez, Navid , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Pant, Shubham , Bekaii-Saab, Tanios S , Pelster, Meredith S , Yan, Xiaohong , Der-Torossian, Hirak , Barve, Minal , Shetty, Aditya, Pant, Shubham

Mayo Clinic

Journal of Clinical Oncology | April 26, 2023 | Volume: 41 | Issue: 25 | Pages: 4097-4106

10.1200/jco.23.00434 | PMID 37099736 Get It

PURPOSE Adagrasib, a KRAS G12C inhibitor, has demonstrated clinical activity in patients with KRAS G12C -mutated non–small-cell lung cancer (NSCLC) and colorectal cancer (CRC). KRAS G12C mutations occur rarely in other solid tumor types. We report evaluation of the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRAS G12C mutation. METHODS In this phase II cohort of the KRYSTAL-1 study (ClinicalTrials.gov identifier: NCT03785249 ; phase Ib cohort), we evaluated adagrasib (600 mg orally twice daily) in patients with KRAS G12C -mutated advanced solid tumors (excluding NSCLC and CRC). The primary end point was objective response rate. Secondary end points included duration of response, progression-free survival (PFS), overall survival, and safety. RESULTS As of October 1, 2022, 64 patients with KRAS G12C -mutated solid tumors were enrolled and 63 patients treated (median follow-up, 16.8 months). The median number of prior lines of systemic therapy was 2. Among 57 patients with measurable disease at baseline, objective responses were observed in 20 (35.1%) patients (all partial responses), including 7/21 (33.3%) responses in pancreatic and 5/12 (41.7%) in biliary tract cancers. The median duration of response was 5.3 months (95% CI, 2.8 to 7.3) and median PFS was 7.4 months (95% CI, 5.3 to 8.6). Treatment-related adverse events (TRAEs) of any grade were observed in 96.8% of patients and grade 3-4 in 27.0%; there were no grade 5 TRAEs. TRAEs did not lead to treatment discontinuation in any patients. CONCLUSION Adagrasib demonstrates encouraging clinical activity and is well tolerated in this rare cohort of pretreated patients with KRAS G12C -mutated solid tumors.
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline
Bixler, Brooke R., Hoffman‐Censits, Jean , Kulkarni, Girish S. , Potretzke, Aaron M. , Smith, Angela B. , Coleman, Jonathan , Clark, Peter E. , Buckley, David , Chang, Sam S. , Chou, Roger , Matin, Surena F. , Pierorazio, Phillip , Psutka, Sarah P. , Raman, Jay D. , Smith, Laura

Mayo Clinic

Journal of Urology | April 25, 2023 | Volume: 209 | Issue: 6 | Pages: 1071-1081

10.1097/ju.0000000000003480 | PMID 37096584 Get It

Female Sexual Dysfunction: A Primer for Primary Care Health Professionals
Thomas, Holly N. , Merriam, Sarah , Kling, Juliana M. , Casas, Rachel S.

Mayo Clinic

MedEdPORTAL | April 25, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11312 | PMID 37113246 Get It

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation.
Pant, Shubham , Yaeger, Rona , Pelster, Meredith , Sabari, Joshua K. , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Pant, Shubham , Spira, Alexander I. , Hafez, Navid , Barve, Minal , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | April 21, 2023 | Volume: 41 | Issue: 36_suppl | Pages: 425082-425082

10.1200/jco.2023.41.36_suppl.425082 Get It

425082 Background: KRAS, a mediator of signalling pathways essential for cellular growth, proliferation, and survival, is the most frequently mutated oncogene in cancer. Notably, KRAS mutations occur in ~90% of pancreatic cancers, of which ~2% are KRASG12C mutations. Other gastrointestinal (GI) tumors also harbor KRASG12C mutations, such as biliary tract cancer (BTC; 1%) and appendiceal cancer (3–4%), and they are also seen in non-GI tumors, such as endometrial and ovarian cancer (1–2%). Adagrasib, a covalent KRASG12C inhibitor that irreversibly and selectively binds KRASG12C in its inactive state, was selected for favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system penetration. Methods: KRYSTAL-1 is a multicohort phase 1/2 study (NCT03785249) evaluating adagrasib in patients (pts) with advanced solid tumors harboring a KRASG12C mutation. Here we report data from a phase 2 cohort evaluating adagrasib monotherapy administered orally at 600 mg BID in pts with unresectable or metastatic KRASG12C-mutated solid tumors (excluding non-small cell lung cancer and colorectal cancer), including pancreatic ductal adenocarcinoma (PDAC), BTC, other GI, and non-GI tumors. Study objectives include evaluation of clinical activity (ORR, DCR, DOR, PFS, OS) and safety. Results: As of October 1, 2022, 64 pts with KRASG12C-mutated solid tumors were enrolled and 63 were treated with adagrasib (median follow-up, 16.8 months); of these, 21 pts had PDAC, 12 BTC, 16 other GI tumors (9 appendiceal, 4 gastro-esophageal junction/esophageal, 3 small bowel), and 14 non-GI tumors (5 ovarian, 4 unknown primary, 3 endometrial, 1 breast, 1 glioblastoma). Overall, median age was 65 years, 61% had ECOG PS 1, and median prior lines of systemic therapy was 2. Among 57 pts with measurable disease (blinded independent central review), ORR was 35.1% (20/57; all partial responses); DCR was 86.0% (49/57); median DOR was 5.3 months (n=20; 95% CI 2.8–7.3); median PFS was 7.4 months (95% CI 5.3–8.6); and median OS was 14.0 months (n=64; 95% CI 8.5–18.6). Among 21 pts with PDAC, ORR was 33.3% (7/21); DCR was 81.0% (17/21); median PFS was 5.4 months (95% CI 3.9–8.2); and median OS was 8.0 months (95% CI 5.2–11.8). Among 12 pts with BTC, ORR was 41.7% (5/12); DCR was 91.7% (11/12); median PFS was 8.6 months (95% CI 2.7–11.3); and median OS was 15.1 months (95% CI 8.6–not estimable). Overall (n=63), treatment-related adverse events (TRAEs) of any grade were observed in 96.8% of pts (most commonly [≥20%] nausea [49.2%], diarrhea [47.6%], fatigue [41.3%], vomiting [39.7%]), grade 3 TRAEs in 25.4%, and grade 4 TRAEs in 1.6%. No grade 5 TRAE occurred. Conclusions: Adagrasib is well tolerated and demonstrates promising clinical activity in pretreated pts with PDAC, BTC, and other solid tumors harboring a KRASG12C mutation. Clinical trial information: NCT03785249 .
D18. Risk of Breast Cancer-Related Lymphedema: Development and Validation of a Clinically-Relevant, Patient-facing Prediction Model
Rochlin, Danielle H. , McLaughlin, Sarah A. , Coriddi, Michelle , Mehrara, Babak J. , Barrio, Andrea V. , Zee, Kimberly J. Van , Dayan, Joseph H.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 21, 2023 | Volume: 11 | Issue: 4S | Pages: 70-71

10.1097/01.gox.0000934684.25197.89 Get It

Hospitalist perspective on pandemic related clinical and administrative changes: a cross sectional survey study
Aksoy, Tulay , Patil, Nikita , Baron, Sarah , Gambhir, Harvir Singh , Mandel, Chiara , Pagali, Sandeep R. , Baron, Sarah W , Pagali, Sandeep

Mayo Clinic

Hospital Practice | April 21, 2023 | Volume: 51 | Issue: 3 | Pages: 149-154

10.1080/21548331.2023.2206230 | PMID 37083176 Get It

CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization
Luebker, Sarah, Frech, Tracy , Skaug, Brian , Gordon, Jessica , Lakin, Kimberly S. , Bernstein, Elana J. , Luo, Yiming , Steen, Virginia , Moore, Duncan F. , Khanna, Dinesh , Castelino, Flavia V. , Chung, Lorinda, Kapoor, Puneet, Hant, Faye N. , Shanmugam, Victoria K. , VanBuren, John M. , Alvey, Jessica S. , Harding, Monica, Shah, Ankoor R. , Lebiedz‐Odrobina, Dorota, Thomas, Julie K. , Volkmann, Elizabeth R. , Molitor, Jerry A., Sandorfi, Nora , Chung, Leland W.K. , Luo, Yiming , Frech, Tracy M , Skaug, Brian , Bernstein, Elana J , Richardson, Carrie , Khanna, Dinesh , Volkmann, Elizabeth R , Chung, Lorinda , Luo, Yiming , Assassi, Shervin , Luo, Yiming, Shah, Ami A. , Hummers, Laura K , Chung, Lorinda, Shah, Ankoor, Makol, Ashima , Thomas, Julie K

Mayo Clinic

Rheumatology | April 20, 2023 | Volume: 62 | Issue: 10 | Pages: 3433-3438

10.1093/rheumatology/kead176 | PMID 37079727 Get It

Abstract Objectives SSc is associated with increased health-care resource utilization and economic burden. The Collaborative National Quality and Efficacy Registry (CONQUER) is a US-based collaborative that collects longitudinal follow-up data on SSc patients with <5 years of disease duration enrolled at scleroderma centres in the USA. The objective of this study was to investigate the relationship between gastrointestinal tract symptoms and self-reported resource utilization in CONQUER participants. Methods CONQUER participants who had completed a baseline and 12-month Gastrointestinal Tract Questionnaire (GIT 2.0) and a Resource Utilization Questionnaire (RUQ) were included in this analysis. Patients were categorized by total GIT 2.0 severity: none-to-mild (0–0.49); moderate (0.50–1.00), and severe-to-very severe (1.01–3.00). Clinical features and medication exposures were examined in each of these categories. The 12-month RUQ responses were summarized by GIT 2.0 score categories at 12 months. Results Among the 211 CONQUER participants who met the inclusion criteria, most (64%) had mild GIT symptoms, 26% had moderate symptoms, and 10% severe GIT symptoms at 12 months. The categorization of GIT total severity score by RUQ showed that more upper endoscopy procedures and inpatient hospitalization occurred in the CONQUER participants with severe GIT symptoms. These patients with severe GIT symptoms also reported the use of more adaptive equipment. Conclusion This report from the CONQUER cohort suggests that severe GIT symptoms result in more resource utilization. It is especially important to understand resource utilization in early disease cohorts when disease activity, rather than damage, primarily contributes to health-related costs of SSc.
Commentary: Daily Pain Prediction Using Smartphone Speech Recordings of Patients With Spine Disease
Bydon, Mohamad , Johnson, Sarah E. , Katsos, Konstantinos, Katsos, Konstantinos D.

Mayo Clinic

Neurosurgery | April 20, 2023 | Volume: 93 | Issue: 3 | Pages: e61-e62

10.1227/neu.0000000000002503 | PMID 37078725 Get It

Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy
Beach, Thomas G. , Sue, Lucia I., Scott, Sarah, Intorcia, Anthony J., Walker, Jessica E. , Arce, Richard, Glass, Michael J. , Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Stewart, Analisa M. , Martinez, Kayleigh N, Krupp, Addison, McHattie, Rylee, Mariner, Monica, Lorenzini, Ileana , Kuramoto, Angela, Long, Kathy E., Tremblay, Cécilia , Caselli, Richard J. , Woodruff, Bryan K. , Rapscak, Steven Z., Belden, Christine M. , Goldfarb, Danielle, Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Driver-Dunckley, Erika D., Adler, C H , Choudhury, Parichita , Sabbagh, Marwan Noel , Atri, Alireza , Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 18, 2023 | Volume: 82 | Issue: 6 | Pages: 457-466

10.1093/jnen/nlad026 | PMID 37071794 Get It

Abstract Cerebral white matter rarefaction (CWMR) was considered by Binswanger and Alzheimer to be due to cerebral arteriolosclerosis. Renewed attention came with CT and MR brain imaging, and neuropathological studies finding a high rate of CWMR in Alzheimer disease (AD). The relative contributions of cerebrovascular disease and AD to CWMR are still uncertain. In 1181 autopsies by the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), large-format brain sections were used to grade CWMR and determine its vascular and neurodegenerative correlates. Almost all neurodegenerative diseases had more severe CWMR than the normal control group. Multivariable logistic regression models indicated that Braak neurofibrillary stage was the strongest predictor of CWMR, with additional independently significant predictors including age, cortical and diencephalic lacunar and microinfarcts, body mass index, and female sex. It appears that while AD and cerebrovascular pathology may be additive in causing CWMR, both may be solely capable of this. The typical periventricular pattern suggests that CWMR is primarily a distal axonopathy caused by dysfunction of the cell bodies of long-association corticocortical projection neurons. A consequence of these findings is that CWMR should not be viewed simply as “small vessel disease” or as a pathognomonic indicator of vascular cognitive impairment or vascular dementia.
Effect of Messaging Content on Engagement With a Short Messaging Service for Perioperative Smoking Cessation
Jose, Thulasee , Cha, Sarah , Graham, Amanda L. , Schroeder, Darrell R. , Warner, David O. , Warner, David O , Jose, Thulasee , Schroeder, Darrell , Graham, Amanda L , Amato, Michael S.

Mayo Clinic

Nicotine and Tobacco Research | April 14, 2023 | Volume: 25 | Issue: 8 | Pages: 1465-1473

10.1093/ntr/ntad061 | PMID 37058426 Get It

Abstract Introduction We determined whether a tobacco cessation intervention targeting brief perioperative abstinence (“quit for a bit”) increased engagement of surgical patients with treatment compared with an intervention targeting long-term postoperative abstinence (“quit for good”). Aims and Methods Surgical patients who smoke were stratified according to intended duration of postoperative abstinence, and then randomized within strata to receive either a “quit for a bit” or a “quit for good” intervention. Both employed initial brief counseling and short message service (SMS) to deliver treatment up to 30 days after surgery. The primary outcome of treatment engagement was defined as the rate at which subjects actively responded to system requests delivered via SMS. Results The engagement index did not differ between intervention groups (median [25th, 75th] of 23.7% [8.8, 46.0] for “quit for a bit” group (n = 48) and 22.2% [4.8, 46.0] for “quit for good” group (n = 50), p = .74), nor did the proportion of patients continuing SMS use after study completion (33% and 28%, respectively). Exploratory abstinence outcomes on the morning of surgery and 7 and 30 days after surgery did not differ between groups. Program satisfaction was high in both groups and did not differ. There was no significant interaction between intended abstinence duration and any outcome, ie, alignment of intent with intervention did not affect engagement. Conclusions Tobacco cessation treatment delivered via SMS was well accepted by surgical patients. Tailoring an SMS intervention to focus on the benefits of short-term abstinence for surgical patients did not increase engagement in treatment or perioperative abstinence rates. Implications Treatment of surgical patients for tobacco use is efficacious and reduces postoperative complications. However, implementation in clinical practice has proved challenging, and new methods of engaging these patients in cessation treatment are needed. We found that tobacco use treatment delivered via SMS was feasible and well utilized by surgical patients. Tailoring an SMS intervention to focus on the benefits of short-term abstinence for surgical patients did not increase engagement in treatment or perioperative abstinence rates. Clinical Trial Number NCT03839043. Registry URL: https://clinicaltrials.gov/ct2/show/NCT03839043